IL21 and rheumatoid arthritis: There is another randomized, double-blind, placebo-controlled study that aims to neutralize IL-21 cytokines using a recombinant α(IL)-21 monoclonal antibody for the treatment of rheumatoid arthritis, but so far only safety endpoints and pharmacokinetics were assessed [75].